Navigation Links
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Date:9/2/2010

>  

STOCKHOLM, September 2, 2010 /PRNewswire/ --

- Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups (diabetes, acute coronary syndrome and multiple lesion). These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at 9 months follow-up and on clinical outcomes at 18 month follow up of the randomized comparison of the CYPHER(R) Stent and the Endeavor(R) Stent.

The initial results of the SORT OUT III study were published in the Lancet and showed significantly reduced adverse events at 9 and 18 months for the CYPHER(R) Sirolimus-eluting Coronary Stent over Medtronic's Endeavor(R) Stent in an unselected group of 2,332 patients undergoing coronary intervention in real world clinical practice. The authors reported that subgroup analysis of the primary endpoint of 9-month Major Adverse Cardiac Events (MACE, defined as a composite of cardiac death, myocardial infarction [MI], or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes, and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at 9 months
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
2. Resverlogix Scientific Data Presented at EAS Congress
3. Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
4. Delcath Highlights Phase III Trial Results Presented at ASCO
5. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
6. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
7. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
9. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
10. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
11. Gramene Announces Scholarships for Groups Underrepresented in Science to Learn How to Use Bioinformatics and Genomics Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... ... PRC Clinical, a Clinical Trial Management Expert CRO, will be ... California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors to ... , Stem Cell Meeting on the Mesa on October 7-9 in ...
(Date:8/25/2015)... CARDIFF, UK (PRWEB) , ... August 25, 2015 ... ... accurately determining whether breast tissue lesions are cancerous is described by University of ... the international society for optics and photonics. , In “ Breast cancer diagnosis ...
(Date:8/25/2015)... Calif. (PRWEB) , ... August 25, 2015 , ... One ... Valley -based Resilinc Corp., Bindiya Vakil, has been on a mission for ... the impact on global supply chain operations - from the two massive explosions that ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... , , ... May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ... for the treatment of cancer, today announced the dosing of the ... with SL052 Photodynamic Therapy in prostate cancer patients. The study will ...
... HARBIN, China , May 11 /PRNewswire-Asia-FirstCall/ -- ... Company") (Nasdaq: CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced the Company attended,the 107th China Import and ... May 1st,to 5th, 2010 and generated significant interest from ...
... N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of ... that it has completed a $10 million financing and expanded its Board ... Joining the Company,s Board of Directors ... , , ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 2China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 4
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... pores ?the all-important channels that control the flow of information ... to prepare for the split to come when a cell ... Institute for Biological Studies watched as new funnel-like pore structures ... , This discovery adds to the picture of how ...
... a protein made by a cancer virus causes infected immune ... to spread. , The virus, the human T lymphotropic ... known as T lymphocytes, or T cells, touch uninfected T ... transmission happens. It suggests that an HTLV-1 protein known as ...
... the lore of marathoners and extreme athletes, lactic acid ... the muscles and leads to muscle fatigue, reduced performance ... the University of California, Berkeley, however, tells a different ... and athletes don't realize it, says exercise physiologist George ...
Cached Biology News:Researchers solve mystery of how nuclear pores duplicate before cell division 2Viral protein helps infected T cells stick to uninfected cells 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 4
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Biology Products: